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Summary 
Natural autoantibodies are primarily immunoglobuhn M (IgM) antibodies that bind to a variety 
of self-antigens, including self-IgG. Accounting for a large proportion of the early B cell repertoire, 
such polyspecific  autoantibodies are speculated to contribute to the homeostasis and/or competence 
of the primary humoral immune system. Recent studies indicate that the leukemia cells from 
most patients with chronic lymphocytic leukemia (CLL) also express such IgM autoantibodies. 
Similarly, the leukemia cells from many CLL patients react with murine monoclonal antibodies 
(mAbs) specific for crossreactive idiotypes (CtLIs) associated with human IgM autoantibodies. 
In particular,  leukemic cells frequently react with G6, a mAb specific for an Ig heavy chain (H 
chain)-associated CRI, and/or with 17.109, a mAb that defines a K  light chain (L chain)-associated 
CRI. Generated against IgM rheumatoid factor (RF) paraproteins, G6 and 17.109 each recognize 
a major CRI that is present in many IgM RF paraproteins. Furthermore, over 90% of the IgM 
paraproteins found to bear both H and L chain-associated CtLls also are found to have tLF activity. 
Molecular characterization of these CILIs demonstrates that each is a serologic marker for expression 
of a highly conserved Ig V gene. As such, the frequent production of IgM polyspecific  autoantibodies 
in CLL simply may reflect the frequent use of such highly conserved autoantibody-encoding 
Ig V genes with little or no somatic mutation. To test this hypothesis,  we generated murine 
transfectomas to pair the 17.109-reactive K  L chain of SMI, a 17.109/G6-reactive CLL population, 
with  the  Ig H  chain of SMI  or other G6-reactive leukemia  cells or tonsillar  lymphocytes. 
Cotransfection of vectors encoding the Ig H and L chains of SMI generated transfectomas that 
produce  IgM~ RF  autoantibodies  reactive  with  human  IgG1  and  IgG4.  In  contrast  to 
G6/17.109-reactive IgM~ ILF Waldenstrom's paraproteins, the SMI IgM~ also reacts with several 
other self-antigens, including myoglobin, actin, and ssDNA. However, cotransfection of the SMI 
L chain  with a vector  encoding any one of 10 different  G6-reactive Ig H  chains generated 
transfectomas  that  produce  IgM~ antibodies  without  detectable  polyspecific  autoantibody 
activity.  These results indicate  that polyspecific antiself-reactivity  of G6/17.019-reactive  Ig is 
dependent on the somatically generated Ig third complementarity determining region. Collectively, 
these studies imply that selection may be responsible for the frequent expression of polyspecific 
autoantibodies  in CLL and early B cell ontogeny. 
r'~he leukemia cells from many patients with chronic lym- 
1  .IL phocytic leukemia (CLL)  produce polyspecific IgM au- 
toantibodies.  Early studies by Prend'homme and Seligmann 
(1) indicated that CLL patients have leukemia cells that fre- 
quently bear surface membrane IgM that has RF activity, 
or binding activity for human IgG. In another limited survey, 
four of thirteen CLL patients were found to have leukemia 
cells that expressed surface IgM (slgM) with binding activity 
I Abbreviations used in this ~per: BBS, borate buffered saline; CLL, chronic 
lymphocytic leukemia;  CKI, crossreactive idiotypes. 
for human IgG (2). Subsequent  studies demonstrated that 
over half of all CLL patients have leukemia cells that can be 
stimulated to secrete autoantibodies  in vitro that bind to a 
variety of self-antigens, most notably human IgG (3-6). Al- 
though each of the leukemia cell cultures in these studies was 
monoclonal, the secreted autoantibodies generally were poly- 
specific, each Ig binding to two or more distinct self-antigens, 
e.g., human IgG, ssDNA, dsDNA, histones, cardiolipin, actin, 
thyroglobulin, and/or cytoskeletal components. Collectively, 
these studies indicate that the leukemia cells from most CLL 
patients  may express polyreactive autoantibodies. 
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with mAbs specific for crossreactive idiotypes (CRIs) of IgM 
autoantibodies. Approximately one-fifth of the patients with 
K L chain-expressing CLL, for example, were found to have 
leukemia cells that express a K  L chain-associated CRI defined 
by a mAb,  designated  17.109  (7,  8).  Furthermore,  a high 
proportion of CLL patients have leukemia cells that react with 
G6 (8, 9), a mAb specific for an Ig H chain-associated CRI. 
Generated against monoclonal IgM RF paraproteins,  both 
17.109  and G6 recognize CRIs present  on many IgM au- 
toantibodies, particularly RFs (10-12).  In addition, over 90% 
of the monodonal IgM paraproteins that have both H  and 
L chain  CRIs are noted to have RF activity (13). 
Evaluation of the molecular basis for expression of these 
CRI reveals that each is a serologic marker for a conserved 
Ig V gene expressed with little or no somatic mutation (14, 
15). For example, the 17.109-reactive  (17.109 +) neoplastic B 
cells  from  unrelated  patients  express  nearly  identical  V~ 
genes that  share more than 99% nucleic acid sequence ho- 
mology with a germline V~III gene isolated from placental 
DNA, designated Humkv325 (14-16). Similarly,  G6-reactive 
(G6 +) leukemia cells from unrelated patients, as well as G6 + 
tonsillar lymphocytes from healthy donors (17), express ho- 
mologous V, genes of the V.1  subgroup,  designated 51pl 
(18,  19).  Conceivably, the frequent  expression of IgM au- 
toantibodies  in  CLL  may be a  direct  consequence  of the 
repeated use of such highly-conserved Ig V genes. This model 
is supported by the work of Sanz et al. (20), suggesting that 
natural polyreactive autoantibodies are encoded by a restricted 
repertoire  of nonmutated  Ig V  genes. 
However, this model minimizes  the contribution  of the 
third CDR (CDR3) to the autoreactive binding activity of 
the Ig expressed in CLL. This region of the Ig H  chain is 
encoded by the D  and J, gene segments,  that  undergo re- 
combination and NH2-terminal  nucleic acid base insertion 
immediately prior to V. gene rearrangement  (21,  22). Ac- 
cordingly,  the sequence of the CDR3 generally is idiosyn- 
cratic to each Ig V. gene rearrangement,  as has been noted 
with all G6 + H  chains sequenced to date (17,  18, and un- 
published observations).  In view of the large potential for 
diversity in the CDR3 of G6 + H  chains (17),  the random 
pairing  of a 17.109 + K L chain  with any G6 + Ig H  chain 
may not be anticipated to form an autoantibody if the CDR3 
is critical to autoantibody binding  activity. 
To examine this, we generated murine transfectomas to pair 
the 17.109 + g L chains of SMI, a  17.109/G6 + CLL B cell 
population, with each of several different G6 + H  chains ex- 
pressed by normal or leukemic B cells. We find that the my- 
eloma cells cotransfected with the original pair of Ig H  and 
L chain genes of SMI secrete polyreactive IgM, RF autoan- 
tibodies. However, myeloma cells co-transfected with the SMI 
L chain gene and any one of ten different G6 H chain genes 
produced IgM~ that failed to have such polyspecific autoreac- 
tivity. Collectively, this study indicates that the polyspecific 
autoreactivity of the "natural" autoantibodies frequently noted 
in CLL and early B cell ontogeny is a selected specificity. 
Materials and Methods 
Antibodies.  Purified polyclonal human IgG was obtained from 
Cappel Research Products (Durham,  NC). We obtained purified 
myeloma proteins of each IgG isotype from Dr. Hans Spiegelberg 
(University of California, San Diego, School of Medicine, La Jolla, 
CA). Another set of purified mydoma proteins of each IgG iso- 
type was purchased from Calbiochem Corp. (San Diego, CA). G6, 
a murine  IgG1  mAb reactive with  an  autoantibody H  chain- 
associated CRI (12) was obtained from Drs. Rizgar Mageed and 
Roy Jefferis (University of Birmingham,  Birmingham,  England). 
DA4-4, an IgG1 anti-human # H chain-producing hybridoma (23), 
was obtained from the American Type Tissue Culture Collection 
(Rockvilh, MD). Anti-human  g or anti-human  X mAb-producing 
hybridomas were as described (7, 14). The IgM~ R.F paraprotein 
BOLL, isolated from the plasma of a patient with mixed cryoglob- 
ulinemia, was donated by Dr. R. Wistar, Jr. (National Naval Med- 
ical Center, Bethesda, MD). The IgM Waldenstrom's paraprotein, 
ME591, is as described (24). MOPC-21, an IgGl~ mouse myeloma 
protein of unknown specificity, was produced by P3X63Ag8 (25). 
This cell line was obtained from the American Type Culture Col- 
lection. Antibodies were precipitated from ascites or culture super- 
natants in 50% ammonium sulfate. After at least I h at 4~  the 
samples were spun for 10 min at 10,000  g. The harvested Ig precipi- 
tate was suspended and dialyzed  extensively  in PBS, pH 7.2. Column 
chromatography of transfectoma Ig was performed with Superose- 
6  TM in PBS at 4~  using an FPLC apparatus (Pharmacia, Uppsala, 
Sweden). 
Vector Constructions.  We isolated the rearranged gene complexes 
encoding the K L chain and the # H chain of G6-CRI+/17.109 - 
CRI + leukemic cells of CLL patient,  SMI. For this we partially 
digested SMI genomic DNA with Sau3a. Large sized fragments 
were isolated on sucrose density gradients for ligation into X dash  TM 
with BamHI compatible overhangs (Stratagene Inc., La Jolla, CA), 
as described (26). For the ~ L chain, a 17.8-kb BamHI fragment 
was isolated that contained the ~ L chain promoter, rearranged V, 
gene, L chain enhancer and ~ L chain constant region exon. This 
fragment was ligated in pSV2-gpt,  a SV40 DNA plasmid vector 
with  the Escherichia coli gpt gene  (Ecogpt), encoding  xanthine- 
guanine phosphoribosyltransferase (27). Expression of this gene 
allows for selection of transfected mammalian cells with myco- 
phenolic acid (27, 28), as described (29) (see Fig. 1 A). In addition, 
a recombinant  clone was isolated from the SMI genomic library 
that contained the rearranged H chain of SMI. An EcoRI/HindIII 
digest of this recombinant  insert yielded a 3.4-kb fragment  that 
contained the Ig promoter,  the functionally rearranged V. gene 
and the H chain enhancer region.  This fragment  was subcloned 
into Bluescript  TM  (Stratagene Inc.). 
Unique restriction  sites were introduced  at sites flanking the 
H chain variable region gene to allow for the removal and subse- 
quent insertion of different rearranged V, genes isolated via PCR. 
For this,  ssDNA was synthesized using  the R408 helper phage 
(Stratagene Corp.). Unique restriction enzyme sites then were in- 
troduced via site-directed mutagenesis using synthetic oligonucle- 
otides  and  the  Oligonucleotide-Directed-Mutagenesis-System TM 
version 2 (Amersham Corp., Arlington  Heights,  IL). A ClaI site 
was introduced 5' of the leader sequence and a SalI site was intro- 
duced 3' of the J, segment.  Mutants  initially were screened by 
digestion  of plasmids prepared  from  independent  colonies and 
checked by dsDNA sequencing using oligonucleotide complemen- 
tary to sequences 100-bp contiguous  to the introduced site, as de- 
scribed (14). 
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onto an 7.4-kb BamHI-HindlII fragment containing the human 
/z constant region exons excised from pN. x-/zTNP (30), that orig- 
inally was derived from the cloned segment ~, C75 (31. This frag- 
ment, in turn, was ligated onto an EcoRI/BamHI fragment of 
pN. x-#TNP (30), containing the E. coli neo  r gene, the SV40 ori, 
pBR322 ori, and ampicillin  resistance gene to create pRTM1 (see 
Fig. 1 B). The plasmid pN. x-/~TNP originally was obtained from 
Dr. M.J. Shulman (University of Toronto, Toronto, Canada) (30). 
Synthetic Oligonucleotides.  PCR primers, site-directed mutagen- 
esis oligonucleotides and probes were synthesized on a Pharmacia 
Gene Assembler (Pharmacia).  Probes were 5' end-labeled with 
3,-[3zP]ATP and polynucleotide kinase,  as described  (7). 
Cloning Rearranged G6-encoding V. Genes Into pRTM1.  Rear- 
ranged G6-encoding V.1 genes isolated from normal tonsillar (17) 
or neoplastic B cells (18) were cloned and sequenced in Bluescript  TM 
(Stratagene Inc.) as described (15, 17,  18). The rearranged V.I 
genes of SIC, HEN, BRA, and HUR were cloned from the genomic 
DNA isolated from CD5 B call lymphoma tissues of patients with 
G6-reactive CLL (8). SMI, AND, and NEI were isolated from G6- 
reactive leukemia cells (18). To clone each rearranged V.1  gene 
into pRTM1, we performed PCR on each recombinant plasmid 
using oligonucleotides  specific for the V.1 leader sequence (dGCA 
TCG ATA ATC ACC ATG GAC), or to a J. consensus  sequence 
(dGCG TCG ACT CTG AGG AGA CGG TGA) that have the 
flanking restriction enzyme sites ClaI or SalI, respectively.  This 
generated PCR products of'v660 bp that were digested with ClaI 
and Sail,  to yield VHl-containing  inserts  that were purified via 
agarose gel electrophoresis.  These inserts were ligated into pRTM1 
that had been digested with SalI and ClaI and then isolated  free 
of the SMI V.1 insert via 0.8% agarose gel electrophoresis.  The 
ligated plasmids each were used to transform XL1Blue  TM (Stratagene, 
Inc.). Ampicillin-resistant  transformants were screened via blot hy- 
bridization with a radiolabeled oligonucleotide (dGCG TAG TTT 
GCT GTA CC) specific for a sequence within the CDR2 of the 
V.1  gene(s)  encoding the G6-CRI,  as described (18, 32). 
Transfectomas.  P3X63-AgS.653,  a nonsecreting mouse myeloma 
cell line (33), was obtained from the American Type Culture Col- 
lection.  These  cells  were  cultured  in  RPMI-1640  (Whittaker 
Bioproducts, Walkersville,  MD) containing 20% FCS (HyClone 
Laboratories, Inc., Logan, UT) and 2-mM r-glutamine (Mediatech 
Inc., Washington, DC). Cells were washed and then suspended 
in ice cold RPMI at 1.5  x  107/ml. One ml of the cell suspension 
was then mixed with 2-mg linearized vector DNA and then trans- 
ferred into a cold plastic cuvette containing two aluminum elec- 
trodes (Bio-Rad Laboratories,  Richmond, CA). An electric pulse 
of 1,000 V/cm with a capacitance  of 960 mF was applied  to the 
solution using a Gene-Pulser  TM apparatus  (Bio-Rad Laboratories), 
as described (34). After the electric pulse,  the cells were kept on 
ice for 10 min and then transferred to a flask of warm culture 
medium. 2 d after the electroporation, the medium was adjusted 
to I mg/ml of G418 (Geneticin; Gibco Bethesda Research Labora- 
tories,  Gaithersburg, MD)  and/or 250 mg/ml xanthine (Sigma 
Chemical Co., St. Louis,  MO),  15 mg/ml hypoxanthine (Sigma 
Chemical Co.), and I mg/ml mycophenolic acid (Sigma Chemical 
Co.), respectively, to select for transfectomas expressing E. coli neo  r 
and/or gpt genes of the transfected plasmids. 
ELISA.  To measure  the  concentrations  of IgM,  IgM,,  or 
CRI-bearing Ig, polystyrene microtiter plates were incubated with 
murine mAbs HB-57 (anti-human IgM), 17.109, or G6, at 5-10 
#g/ml of borate buffered saline (BBS, pH 8.2).  After incubation 
for over 1 h, plates were washed and then exposed to 1% bovine 
gelatin (J. T. Baker Inc., Phillipsburg, NJ) in BBS for 1 h at room 
temperature to block residual protein binding sites. Culture super- 
natants,  concentrated  transfectoma  Ig,  or  purified  IgM~ para- 
protein were titrated in 1% gelatin in BBS and then added to the 
washed plates for a 1 h incubation at room temperature. Plates were 
then washed with 0.05% Tween in BBS before addition of alkaline 
phosphatase-conjugated goat antibodies specific for the human Ig 
/z chain or ~ L chain (Southern Biotech., Birmingham, AL) to assay 
for IgM or IgM~, respectively.  After another 1-h incubation at 
room temperature, plates were washed and then developed with 
aminoethylcarbozole in carbonate buffer (pH 9.8). The optical den- 
sity at 405 nm of each of the wells was  accessed using a Ther- 
moMax  TM (Molecular Devices Corp., Menlo Park, CA) ELISA plate 
reader linked to a Macintosh  pl~s (Apple Computer, Cupertino, CA) 
computer for protein concentration analyses using A SOFT  TM soft- 
ware (BioMetallic Inc., Princeton, NJ). For standards we used the 
IgM,  RF  paraprotein,  BOIL,  and  an  IgM~  Waldenstrom's 
paraprotein, ME591, of irrelevant specificity. Binding to other self- 
antigens was measured similarly, except that the polystyrene plates 
were coated with bovine actin, bovine thyroglobulin, purified sin- 
glestranded  calf  thymus  DNA  (Sigma  Chemical  Co.),  poly- 
deoxyinosine (poly dI), or poly-deoxythymidine (poly dT) (Phar- 
macia Inc., Piscataway, NJ). Plates without antigen but treated with 
1% gelatin were used to measure gelatin binding activity. For this, 
test samples were diluted in 1% BSA faction V (Boehringer Mann- 
heim Biochemicals, Indianapolis, IN), or in 0.05% gelatin without 
any detectable difference  in plate binding activity. 
To evaluate the ability of anti-idiotype to inhibit antigen binding, 
varying amounts of murine mAb were added to individual wells 
containing SMI IgM~ at a final concentration of 2 #g/ml. After 
a 30-min incubation at room temperature, the samples were as- 
sessed for their ability to bind antigen-coated plates,  as described 
above. The binding activities of antibody with inhibitor were com- 
pared with those of serial dilutions of antibody without inhibitor 
to obtain the effective antigen-binding antibody concentrations. 
The percent inhibition of antigen binding was calculated as [1-(effec- 
tive antigen-binding antibody concentration)/(actual concentra- 
tion)]  x  100. 
Results 
We generated transfectomas to pair different G6 + IgM H 
chains with  the  17.109 +  ~ L  chain of SMI,  a  17.109/G6 + 
CLL cell population. For this, we generated ptLTM1, a human 
#  chain expression vector (Fig.  1 B).  This vector contains 
the functionally rearranged SMI V.I gene flanked by unique 
restriction enzyme sites, ClaI and SalI, that were introduced 
via site-directed mutagenesis.  This vector enabled us to ex- 
change  the SMI H  chain variable with  any one of several 
different functional V.DJ. exons of other G6 + leukemia cells 
or tonsillar lymphocytes. 
From pRTM1, we generated ten additional vector constructs 
that encode highly homologous Ig H  chain variable regions 
(Fig. 2). Each variable region is encoded by a rearranged V.1 
gene that shares >99%  nucleic acid sequence homology to 
51pl,  a V.1  gene expressed during early fetal development 
(17-19,  and unpublished observations). Like SMI,  H  chain 
constructs SIC, HEN,  AND,  NEI, BRA,  and HUR  were 
derived using  the  rearranged  V.1  gene  expressed by G6 + 
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Figure 1.  Structure of pSVG-Vk3 and pRTM1 plasmids. (*-) Direc- 
tions of gene transcription; (open  labeled boxes) important regions. (a) pSVG- 
Vk3 contains the functionally  rearranged Humkv325 Vx gene and C~ exon 
of SMI (17.8 kb) that was inserted into the BamHl site of pSVG-gpt (27, 
28). VK, Humkv325 of SMI rearranged with J~l; C~, K  L chain constant 
region exon; gpt, Ecogpt and SV40 origin of replication: Ori, pBR322 
origin of replication; Amp, ampiciUin resistance gene. (b) pRTM1 con- 
tains the modified and functionally rearranged V, gene of SMI and Ig 
H chain enhancer (3.4 kb) that was inserted between the EcoRI-HindIII 
sites of pN. x-/~TNP (30), that previously  flanked the functionally rear- 
ranged mouse V.TNP gene. VH, the V.1 gene expressed by SMI that 
is functionally  rearranged to J.4, and modified via site-directed mutagen- 
esis to have unique flanking restriction enzyme sites Clal and SalI; E, the 
Ig H chain enhancer region; C/t, exons encoding the human C~ constant 
region; Mem, C~ membrane exon; Neo, the bacterial gene conferring ne- 
omycin resistance, the SV40 origin and SV40 early region; Ori, pBR322 
origin of replication; Amp, ampicillin resistance gene. 
CLL (8,  18,  and unpublished  observations).  H  chain con- 
structs L26, L30, L33, and L42 were derived from the rear- 
ranged  V.1  genes expressed by G6 + tonsillar  B cells  (17). 
From amino acid positions 1-94,  L30 shares  complete ho- 
mology with SMI (Fig. 2). All other V.1 genes have a GAA 
codon instead of an AAA codon at amino acid position 73, 
resulting in a lysine to glutamine  substitution in the third 
framework region (Fig. 2). In addition, BRA has two other 
nonconservative nucleic acid base differences from SMI that 
result in serine to asparagine substitutions at amino acid po- 
sitions 35 and 76. For comparison, the amino acid sequence 
of  the  H  chain  variable  region  of  the  G6 +  IgM,  RF 
paraprotein  BOR  (35)  differs  from  SMI  by nine  residues 
(Fig. 2). 
In  contrast  to  the  relative  uniformity  in  the  V.  gene- 
encoded protein  sequences, the rearranged  V.  genes differ 
markedly in the CDR3s (Fig.  2).  In addition,  the lengths 
of the CDR3s vary greatly, ranging from 6-25 codons (L26- 
SIC). Finally,  rearranged J. gene segments J,3, J.4, J.5, and 
J,6 are represented in this collection of G6 + H  chain vari- 
able regions  (Fig.  2). 
To generate transfectomas expressing each of these H chains 
with  a  17.109 +  L  chain,  we  generated  pSVG-VK3. This 
vector contains the genomic DNA of the rearranged K L chain 
gene complex of SMI that encodes a 17.109 + L chain (Fig. 
1 A).  Two other G6 + neoplastic B cell populations  repre- 
sented in this study, SIC and BRA, also originally expressed 
17.109 + K L chains (15). In addition,  the reference IgM, RF 
paraprotein BOR also bears the 17.109 CRI (35). The deduced 
or actual protein sequences of these x variable regions are highly 
homologous, reflecting expression of the conserved V, gene, 
Humkv325, with little or no somatic mutation (Fig. 3) (7, 
15,  16). 
Cotransfection  with  pSVG-VK3 and  the  different  con- 
structs of pR,TM1 generated transfectomas that each secreted 
intact human IgMK protein. Sample concentrations were de- 
termined via ELISA using monoclonal  IgM~ paraproteins, 
ME591 and/or BOR, as standards.  The amounts of measured 
IgM~ protein  in the  supernatants  varied between different 
transfectoma cell lines,  ranging  from a few hundred  nano- 
grams to several micrograms of antibody per ml. However, 
the Ig concentration of each supernatant assessed using plates 
coated with anti-human/z  chain mAb was comparable to 
that determined using plates coated with G6, 17.109, or mAbs 
specific for human K L chains (data not shown). Column chro- 
matography of transfectoma proteins SMI, HEN, SIC, or L26 
revealed the measured IgM, or Ig x activity to have a mo- 
lecular size similar to that of IgG (data not shown). Collec- 
tively, these results indicate that each transs  apparently 
produces intact monomeric IgM, molecules that bear both 
17.109  and G6 CRIs. 
Although each transfectoma secretes  intact G6 +/17.109 + 
IgM,,  only the cell lines  generated using the  Ig H  and L 
chain genes of SMI produced IgM, with significant RF ac- 
tivity.  Serial  dilutions  of  concentrated  IgM~  from  each 
sample were assayed for binding activity to human IgG. The 
IgMK  produced  by  the  transfectoma  expressing  both  Ig 
chains of the SMI leukemia cell population (designated SMI) 
has detectable RF activity at concentrations below 1 #g/ml 
(Fig.  4).  At any one IgM,  concentration,  the  RF activity 
of SMI  is  lower  than  that  of the  multimeric  IgM~  RF 
paraprotein,  BOR (Fig.  4). However, except for L30, none 
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1  20  +---+  40  +  .........  60  ....  +  80  94+  .........................  +103 
SMI  Q~QLVQSGAEVKKPGS~VKV~CKASGGTF~SYAISWVRQA~GQG~EWMGGII~IFGTANYAQKFQGRVTITADKSTSTAY~LSSLRSEDTAVYYCAR  GGNYDYIWGSYRSND  AFDIWGQGTMVTVSS  JH3 
SIC  .........................................................................  E ........................  N -  YCGGDCY -  RWE  LLR~DFSED  ......  P ........  JH  3 
MEN  .........................................................................  E ........................  PH~SIDDFW -  GYYPN  YYYYGM-  V .....  T .....  JH6 
AND  .........................................................................  E ........................  VSIFGVVQH  YYYYYYM'V. -K..T  .....  JH6 
NEI  .........................................................................  E .........................  PRLLADVLLWFGELS  E''Y  .....  L  .....  JH4 
BRA  ..................................  N ......................................  E''N  .....................  D-  CSGGSCYFW  GW''P .....  L  .....  J~5 
HUR  .........................................................................  E ........................  VP-PLFFAV  GM'V  .....  T .....  JH6 
L26  .........................................................................  E .........................  D  NW--p .....  L  .....  JH  5 
L30  ...................................  =  ...............................................................  RTRVSVSTL'D  "SGYYDFSG  YYGM'V .....  T .....  JH6 
L33  .........................................................................  E .........................  YYYYYGM'V .....  T .....  JH  6 
L42  .........................................................................  E ..........................  VAGRPHFD  Y .....  L  .....  JH  5 
BOR  E ...................  T .....  D  ....  S .........................  P  .............  T'E  ........  V  .........  L  .....  E - RP,  MA - I',lP  "'Y  .....  L  .....  JH4/5 
Figure 2.  Sequence comparison  of the deduced or actual amino add sequences of G6 + Ig H chain variable regions. (Right) Code name for each 
sequence. The 20-letter amino acid code represents the deduced sequence of SMI. All other sequences are compared with that of SMI. (-) Homology 
between the compared sequences and SMI. Otherwise, letters correspond to the discordant amino acids. Spaces are introduced to maximize sequence 
homology in CDR3.  Listed above SMI, amino acid residues are numbered according to Kabat et al. (51). Also listed are labels indicating  the first, 
second,  and third CDRs, and the region encoded by the J. gene segment. (left) Deduced J. gene segments  used to encode the fourth framework of 
the H  chain variable regions.  At the bottom of the figure is the actual amino acid sequence of BOR. (35)  compared to that of SMI. 
SMI 
SIC 
BRA 
CDRI  CDR2  CDR3  JK 
1  24  ........  34  50-----56  89  .....  97  .........  107 
EIvLTQSPGTLSLSPGERATLScRASQsvS•SYLAWYQQKPGQAPRLLIYGASSRATGIPDRFsGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPAFGQGTKVEIKRJ•• 
...........................................................................................  NT--G'S  ......  JK4 
.............................................................................................  RYT  ...........  JK  2 
BOR  ....................................................................................  V ...........  QT ...........  JK1 
Figure 3.  Sequence comparison of the deduced or actual amino acid sequences of 17.109 + Ig L chain variable regions. The amino acid sequences 
are described, and compared to SMI as in Fig.  2 
of the other transfectomas IgM, proteins had any detectable 
ILF activity, even at their highest concentrations (>2/~g/ml 
for all except for AND [0.6/~g/ml]) (Fig. 4). Furthermore, 
although L30 had slight reactivity with human IgG, its RF 
activity  only  was  detectable  at  concentrations  exceeding 
1 #g/ml  (Fig.  4). 
The SMI  IgM, ILF is isotype specific.  SMI  has binding 
activity for IgG1 or IgG4 myeloma proteins that is similar 
to that for total human IgG (Fig. 5). In contrast, SMI binds 
poorly to IgG2 and IgG3.  The same hierarchy of binding 
activity for IgG1 >  IgG4 >> IgG2 >  IgG3, is noted using 
either of two sets of purified myeloma proteins representing 
each of the IgG isotypes. As such, the reactivity of the SMI 
IgM, for IgG1  or IgG4 cannot be ascribed to an idiosyn- 
RF Activity vs. IgM Concentration 
AND  ~  N,  B~A 
HUN 
1 "  L33 
L42 
BOR 
o-~-  ~.---- = 
1  2  3  4  5  6 
IgM (p.g/ml) 
Figure 4.  RF activity of each transfectoma  protein compared with BOR. 
Ordinate is OD at 405 nm of the ELISA for RF activity measured on 
plates coated with total human IgG. The abscissa describes the IgM, con- 
centration (/zg/ml) of the assayed sample. Symbols representing titration 
of each sample are indicated. In particular, (O) BOR, (A) SMI, and (D) 
binding activity of L30. 
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cratic binding activity for a particular myeloma protein of 
a single donor. Of note, the BOR IgM~ RF paraprotein also 
reacts primarily with  IgG  of the IgG1  isotype  (data not 
shown). 
In contrast to BOIL and each of the other transfectoma 
proteins, the SMI Ig also has polyspecific antigen binding 
activity.  The  SMI  IgM,  reacts  strongly with myoglobin, 
actin, or ssDNA,  and, by comparison, weakly with thyro- 
globulin (Fig. 6). That the ssDNA binding activity cannot 
be ascribed to trace residual chromatin is demonstrated by 
SMI's reactivity with synthetic polydeoxyinosine (poly dI) 
or polydeoxythymidine (poly dT) (Fig. 6). In every case, the 
binding activity of SMI for each of these antigens is detect- 
able at IgM, concentrations below 1 #g/ml. In contrast, none 
of the other transfectomas  IgM,  proteins,  including L30, 
had detectable binding activity to any of these antigens, even 
IgG Isotype Specificity of SMI 
O  ~  IgG1 
~l"  ￿9  IgG2 
a  1  0  ~'  IgG3 
----o---  tgG4 
￿9  IgG (Total) 
0 
1  2  3  4 
IgM (p_g/ml) 
Figure 5.  IgG isotype specificity of SMI. Graph labeled as in Fig. 4. 
Symbols represent titration of SMI on plates coated with IgG1 (O), IgG2 
(@),  IgG3  (A), IgG4 (I-3), or total  IgG  (11),  respectively. Polyspecific Binding Activity of SMI 
3 
￿9  myoolobJn 
actin 
2  ￿9  ssDNA  tt3 
~  poly dl 
r'~  .L  OOfy  C~  o 
1  ~  thyroOlobulin 
￿9  gelatin 
0 
o  ,  ; 
IgM (gg/mt) 
Figure 6.  Polyspecific  binding activity  of SMI. Graph labeled  as in Hg. 
4. Symbols  represent titration of SMI on plates coated  with myoglobin 
(o), actin (1"3), single-stranded  DNA (Q), poly deoxyinosine  (A), poly 
deoxythymidine  (A), thyroglobulin  (O), or gelatin (11), respectively. 
80 
g 
~  60 
-  4o 
2O 
Competitive  Inhibition by Anti-CRI 
C-21 
O 
o.o  ols  ;'o  ,is  ;0 
Molar Ratio 
Fig~ 8.  Inhibition  of SMI antigen  binding activity  by anti-CRl mAb. 
Ordinate lists percent  inhibition  of  SMI binding  to myoglobin-coated  phtes 
by preincubation  of SMI with either 17.109 (@), G6 ([-3), or MOPC-21 
(A), calculated  as described  in Materials  and Methods.  The measured  values 
are plotted against the molar ratio of anti-idiotypic  or MOPC-21 inhib- 
itor to SMI IgM,. 
at the highest tested concentration of >2 #g/ml for all ex- 
cept AND (1.6 #g/ml) (data not shown). In addition, the 
IgM, RF,  BOP,,  also did not have any detectable binding 
activity for any of these antigens, even at concentrations in 
excess of 4/~g/ml.  None of the transfectoma proteins, in- 
cluding SMI, had significant binding activity for bovine gelatin 
(data not shown,  and Fig.  6). 
We size fractionated the SMI IgM, via FPLC and evalu- 
ated each fraction for antigen binding activity by ELISA. These 
analyses revealed that the predominant IgM actin-binding ac- 
tivity of SMI is similar in size to monomeric IgG (Fig.  7). 
Similarly, the IgM antimyoglobin binding activity of SMI 
also comigrated with human IgG (data not shown). These 
results demonstrate that the observed polyspecific  antigen- 
binding activity of SMI is not dependent on a multimeric 
structure. 
Finally, the polyspecific binding activity of SMI could be 
inhibited specifically by anti-CRI mAbs. Varying amounts 
of IgG murine mAbs were added to individual wells con- 
taining SMI IgM, at a final concentration of 2/~g/ml. After 
a 30-min incubation at room temperature, the samples were 
assessed for their ability to bind myoglobin via ELISA.  The 
FPLC of SMI Actin Binding Activity 
0.6 
0.4  ~  ActmBinding 
￿9  IgM 
02~  IgG 
0.0o  ~  o  ~  N 
Fraction 
Figure 7.  Size  chromatography of SMI antigen binding activity. The 
SMI IgM, was size fractionated  via FPLC. Each fraction was assayed for 
human IgM anti-actin activity by ELISA. The ELISA OD at 405 of SM! 
(O) is plotted against the fraction sample number.  Also shown are ODs 
at 2,80 nm of the sample fiactions of ME591, a pentameric Waldenstrom's 
!gM, paraprotein  (I-I), or monomeric lgG (A). 
percent inhibition of antigen binding were plotted versus the 
molar ratios of murine IgG inhibitor to SMI IgM. We find 
that either 17.109 or G6 can completely inhibit SMI antigen 
binding activity at molar ratios in slight excess of unity (Fig. 
8). In contrast, MOPC-21, a control mouse myeloma IgG1 
protein of unknown specificity, did not inhibit SMI antigen 
binding activity (Fig.  8). 
Discussion 
This study demonstrates that the random pairing of different 
G6 § Ig H chains with a single 17.109 § ~c L chain generally 
does not produce an IgM autoantibody. Of 11 murine trans- 
fectomas that  express  IgM~  proteins bearing both  the G6 
and 17.109 CRIs, only the native Ig H and L chain pair had 
significant autoantibody activity. This cannot be attributed 
to defective Ig synthesis by the other transfectomas. The cul- 
ture supernatants of each transfectoma were found to have 
stoichiometric concentrations of Ig #  chains and K L chains 
by F_LISA. Furthermore, ELISA plates coated with either anti-x 
L chain antibodies or anti-CRI mAbs captured amounts of 
transfectoma IgM that were similar to those of anti-hu-IgM- 
coated plates.  Finally, column-chromatography of represen- 
tative samples of the IgM antibodies from those with or 
without RF activity indicated that these proteins have a mo- 
lecular size similar to that of monomeric lgG. Collectively, 
these results indicate that each transfectoma produces intact 
monomeric human IgM~ molecules bearing both 17.109 and 
G6 CRIs. We conclude that the random pairing of different 
G6 + Ig H  chains with  17.109"  K L chains generally does 
not generate an Ig with antisdf reactivity. 
The H  chain constant regions of the transfectoma IgM 
proteins examined in this study are encoded by human Cu 
exons derived from an  IgM expression vector, designated 
pN. x-#TNP. In previous studies, Boulianne et al. noted that 
Sp2/0 cells cotransfected with pN. x-/zTNP and an Ig L chain 
expression vector secreted mostly multimeric lgM (30). How- 
ever, as noted above, we found that most of the IgM secreted 
by each transfectoma comigrates with monomeric human IgG 
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cessing procedures  may have influenced  the ratio of IgM 
monomers to IgM multimers that is secreted by our trans- 
fectomas (Dr. Marc J. Shulman, personal communication). 
Alternatively, a mutation(s) may have occurred in the human 
Cu exons during the construction of pKTM1, resulting in 
a vector that encodes Ig/x chains that are inefficient in forming 
multimers (36, 37). Restriction mapping studies of pKTM1 
and pN. x-#TNP, however, failed to reveal any differences 
between the two vectors in the regions containing the Ig C~ 
exons (data not shown). In any case, all transfectomas used 
in this study possessed the same Ig C, exons, were cultured 
under similar conditions and apparently secreted  mostly mono- 
meric IgM. Furthermore, most oflgM autoantibody activity 
of SMI also chromatographically comigrates with human IgG 
(Fig. 7). Therefore,  the differences in the binding activities 
of the transfectoma proteins bearing both 17.109 and G6 CRIs 
cannot be ascribed to simple differences  in Ig receptor valency. 
The V.1 exon of SMI differs from those of most other 
transfectomas by a single nonconservative base substitution 
at amino acid position 73, resulting in a glutamine to lysine 
substitution (Fig. 2). Although this substitution may be due 
to somatic mutation, this difference also may reflect a genetic 
polymorphism in the V,1 gene encoding the G6-CILI, Pos- 
sibly, the lysine residue at position 73 contributes to the RF 
binding activity of the SMI transfectoma protein. In this re- 
gard, it should be noted that L30, the only other transfec- 
toma IgM with lysine at amino acid position 73 (Fig. 2), 
also is the only other transfectoma protein that has binding 
activity for IgG that is above background (Fig. 4). It is not 
likely that this substitution enhances the ILF activity of G6- 
reactive IgM proteins, in general, however, as most other G6- 
reactive ILF autoantibodies  and CLL Ig do not have a lysine 
at this position (e.g., BOIL, Fig. 2, and references 12, 13, 
35). Another possibility is that the CDR3 of the SMI L chain 
may have been selected for its ability to generate an ILF Ig 
when paired with a G6-reactive H  chain that has a lysine 
at this position. Evaluation  of the relative contribution of 
this lysine residue to the ILF activity of SMI may require site- 
directed mutagenesis studies and/or further chain mixing ex- 
periments. 
In any case, the present  study delineates the importance 
of the CDR3 to the polyspecifc binding activity of Ig bearing 
these autoantibody-associated  CILIs. Each of the G6 + H 
chains has a unique CDR3 sequence. However, except for 
the lysine to glutamine substitution at position 73, the V. 
gene-encoded protein sequences for all but one of the trans- 
fectoma proteins  are identical.  Moreover, L30 shares com- 
parable homology with SMI in the V. gene-encoded pro- 
tein sequence. Since the pairing of L30 with the 17.109  + 
SMI L chain does not produce an Ig with detectable poly- 
specifc autoantibody reactivity, this amino acid substitution 
alone cannot account for the absence of such binding activity 
in the other transfectoma proteins.  Collectively, these data 
argue that the somatically generated CDIL3 may contribute 
significantly to the polyspecific autoantibody activity of cer- 
tain G6 +  /  17.109  + IgM proteins. 
This indicates that such polyspecific binding activity of 
natural autoantibodies  may be a selected specificity. In the 
primary follicles of human fetal spleen, high proportions of 
B cells express autoantibody-associated CRIs, such as G6 and 
17.109 (38). Genetic mechanisms may favor the frequent rear- 
rangement of Ig V genes that have the capacity to encode 
CILI-bearing IgM autoantibodies (39). However, as with our 
transfectoma studies, the random pairing of such Ig L and 
H chains during ontogeny may infrequently give rise to Ig 
with polyspecific antiself-reactivity. Conceivably, B cells that 
chance express functional and self-reactive receptors may be 
stimulated  to mature into functional B lymphocytes.  Such 
selection may contribute to the noted high frequency of B 
cell clones expressing such polyreactive natural autoantibodies 
during early development (40, 41). Indeed, recent data indi- 
cate that most peripheral B cells in mice may be ligand selected 
(42). The selection for self-reactive autoantibody-expressing 
B cells during B cell ontogeny may be similar to that of T 
cells in the thymus, where only the cells expressing receptors 
with low affinity antiself-reactivity are selected for subsequent 
T  cell maturation (43-47). 
With regard to CLL, it is not certain whether the apparent 
selection for polyreactive autoreactivity merely reflects its cyto- 
genesis, or if it actually plays a role in leukemogenesis (48, 
49).  Recent studies indicate that most patients  with CLL 
have leukemia cells that express IgM autoantibodies that, like 
the SMI transfectoma IgM~, react with a variety of different 
self antigens (3-6). The frequency of CLL patients that have 
leukemia B cells that express such polyreactive autoantibodies 
apparently greatly exceeds the noted frequency of polyreac- 
tive B cells in normal embryonic tissues, cord blood or adult 
peripheral blood. Whatever the origin, Guigou et al. (50) 
recently noted that  11-16%  of the EBV-transformed  Ig- 
secreting B cell clones expressed polyspecific antibodies when 
tested on a panel of nine antigens,  including self-antigens. 
Conceivably, B cells selected for expression of slg with au- 
toantibody activity during early B cell ontogeny could be 
stimulated constitutively by self-antigen, thus increasing the 
risk for malignant transformation to CLL. 
Finally, chance somatic mutation in the V genes encoding 
such self-reactive antibodies may enhance the affinity of the 
expressed Ig for self-antigen, contributing to augmented cell 
stimulation and B cell maturation. Unlike CLL, the neoplastic 
cells in patients with Waldenstrom's macroglobulinemia and/or 
mixed cryoglobulinemia have differentiated into Ig secreting 
cells. The IgM~ KF paraprotein BOK was isolated from the 
plasma  of one such patient.  It is important to note that 
the Ig H chain of the KF paraprotein BOR differs from the 
deduced amino sequence of 51P1 or SMI by several residues 
(35). Conceivably, these differences are secondary to somatic 
mutations that result in loss of polyspecifc autoreactivity and 
higher affinity for the driving self-antigen(s), possibly human 
IgG. Further comparative studies on the structure-function 
relationships of such IgM autoantibodies  may help elucidate 
factors involved in the etiopathogenesis  of these lympho- 
proliferative diseases. 
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